301075 多瑞医药
已收盘 07-18 15:00:00
资讯
新帖
简况
西藏板块盘中拉升,多瑞医药涨3.60%
自选股智能写手 · 07-11
西藏板块盘中拉升,多瑞医药涨3.60%
多瑞医药(301075)7月8日主力资金净卖出53.60万元
证券之星 · 07-09
多瑞医药(301075)7月8日主力资金净卖出53.60万元
多瑞医药(301075.SZ)收到左氧氟沙星氯化钠注射液药品注册证书
智通财经 · 07-08
多瑞医药(301075.SZ)收到左氧氟沙星氯化钠注射液药品注册证书
多瑞医药最新公告:全资子公司获得左氧氟沙星氯化钠注射液药品注册证书
证券之星 · 07-08
多瑞医药最新公告:全资子公司获得左氧氟沙星氯化钠注射液药品注册证书
多瑞医药:公司暂无相关领域的产品
证券之星 · 06-26
多瑞医药:公司暂无相关领域的产品
多瑞医药新提交2件商标注册申请
证券之星 · 06-20
多瑞医药新提交2件商标注册申请
多瑞医药(301075)6月7日主力资金净买入24.39万元
证券之星 · 06-11
多瑞医药(301075)6月7日主力资金净买入24.39万元
多瑞医药(301075)股东西藏嘉康时代科技发展有限公司质押173万股,占总股本2.16%
证券之星 · 06-07
多瑞医药(301075)股东西藏嘉康时代科技发展有限公司质押173万股,占总股本2.16%
多瑞医药(301075.SZ)2023年度权益分派:每10股派1.25元
智通财经 · 05-23
多瑞医药(301075.SZ)2023年度权益分派:每10股派1.25元
多瑞医药:公司暂无相关领域的布局
证券之星 · 05-10
多瑞医药:公司暂无相关领域的布局
多瑞医药(301075)2024年一季报简析:增收不增利
证券之星 · 04-26
多瑞医药(301075)2024年一季报简析:增收不增利
多瑞医药(301075.SZ)发布一季度业绩,净亏损253.73万元,同比扩大4.97%
智通财经 · 04-24
多瑞医药(301075.SZ)发布一季度业绩,净亏损253.73万元,同比扩大4.97%
多瑞医药:拟投资取得红熙医疗51%股权 进一步丰富公司业务布局
财华社 · 01-17
多瑞医药:拟投资取得红熙医疗51%股权 进一步丰富公司业务布局
多瑞医药(301075.SZ)拟控股红熙医疗 进入慢性肾病管理领域
智通财经网 · 01-17
多瑞医药(301075.SZ)拟控股红熙医疗 进入慢性肾病管理领域
加载更多
公司概况
公司名称:
西藏多瑞医药股份有限公司
所属行业:
医药制造业
上市日期:
2021-09-29
主营业务:
西藏多瑞医药股份有限公司主要从事化学药品制剂及其原料药的研发、生产和销售业务。公司的主要产品为醋酸钠林格注射液等。
发行价格:
27.27
{"stockData":{"symbol":"301075","market":"SZ","secType":"STK","nameCN":"多瑞医药","latestPrice":15.08,"timestamp":1721286201000,"preClose":15.08,"halted":0,"volume":807200,"delay":0,"floatShares":27423700,"shares":80000000,"eps":0.2342,"marketStatus":"已收盘","marketStatusCode":5,"change":0,"latestTime":"07-18 15:00:00","open":15.06,"high":15.2,"low":14.58,"amount":12000700,"amplitude":0.0411,"askPrice":15.09,"askSize":2,"bidPrice":15.08,"bidSize":148,"shortable":0,"etf":0,"ttmEps":0.2342,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721352600000},"adr":0,"adjPreClose":15.08,"symbolType":"stock","openAndCloseTimeList":[[1721266200000,1721273400000],[1721278800000,1721286000000]],"highLimit":16.59,"lowLimit":13.57,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":80000000,"pbRate":1.61,"roa":"--","roe":"--","epsLYR":0.24,"committee":0.840319,"marketValue":1206000000,"floatMarketCap":414000000,"peRate":64.389411,"changeRate":0,"turnoverRate":0.0294,"status":2},"requestUrl":"/m/hq/s/301075","defaultTab":"news","newsList":[{"id":"2450683872","title":"西藏板块盘中拉升,多瑞医药涨3.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450683872","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450683872?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:55","pubTimestamp":1720662901,"startTime":"0","endTime":"0","summary":"07月11日,西藏板块盘中拉升,截至09点54分,西藏板块整体指数上涨1.02%,报1420.530点。从个股上来看,该板块的成分股中,多瑞医药涨3.60%,西藏城投、*ST西发、易明医药涨幅居前。从资金上来看,截止发稿,西藏板块主力净流入为-1430.80万,其中西藏城投受到资金热捧,主力净流入904.37万;拉长时间线来看,该板块近20日主力资金净流入-10.63亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110955019681bbe3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110955019681bbe3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","BK0139","BK0028","BK0273","301075","600773","BK0033","BK0239"],"gpt_icon":0},{"id":"2450582930","title":"多瑞医药(301075)7月8日主力资金净卖出53.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450582930","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450582930?lang=zh_cn&edition=full","pubTime":"2024-07-09 09:24","pubTimestamp":1720488262,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月8日收盘,多瑞医药报收于15.31元,下跌4.73%,换手率3.8%,成交量1.04万手,成交额1613.26万元。近5日资金流向一览见下表:多瑞医药融资融券信息显示,融资方面,当日融资买入78.12万元,融资偿还88.6万元,融资净偿还10.48万元。多瑞医药主营业务:化学药品制剂及其原料药的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900014060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2449248587","title":"多瑞医药(301075.SZ)收到左氧氟沙星氯化钠注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449248587","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449248587?lang=zh_cn&edition=full","pubTime":"2024-07-08 17:24","pubTimestamp":1720430645,"startTime":"0","endTime":"0","summary":"智通财经APP讯,多瑞医药(301075.SZ)发布公告,公司全资子公司湖北多瑞药业有限公司近日收到国家药品监督管理局核准签发的关于左氧氟沙星氯化钠注射液的《药品注册证书》,该药品适用于敏感细菌所致的下列感染:慢性支气管炎急性细菌性感染、社区获得性肺炎(包括由衣原体、支原体弓|起的社区获得性肺炎)和医院获得性肺炎、急性上额窦炎、急性单纯性下尿路感染、复杂性尿路感染、急性肾盂肾炎、复杂性和非复杂性皮肤及软组织感染等由敏感细菌引起的感染。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1147001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2449721469","title":"多瑞医药最新公告:全资子公司获得左氧氟沙星氯化钠注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449721469","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449721469?lang=zh_cn&edition=full","pubTime":"2024-07-08 17:20","pubTimestamp":1720430401,"startTime":"0","endTime":"0","summary":"多瑞医药公告,全资子公司湖北多瑞药业有限公司近日收到国家药品监督管理局核准签发的关于左氧氟沙星氯化钠注射液的《药品注册证书》。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800024088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2446354292","title":"多瑞医药:公司暂无相关领域的产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2446354292","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446354292?lang=zh_cn&edition=full","pubTime":"2024-06-26 17:06","pubTimestamp":1719392771,"startTime":"0","endTime":"0","summary":"证券之星消息,多瑞医药(301075)06月26日在投资者关系平台上答复投资者关心的问题。投资者:董秘您好!公司在艾滋病领域有何技术和产品发挥?多瑞医药董秘:您好!感谢您的关注!公司暂无相关领域的产品,谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600035327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2444257863","title":"多瑞医药新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2444257863","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444257863?lang=zh_cn&edition=full","pubTime":"2024-06-20 14:00","pubTimestamp":1718863249,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日西藏多瑞医药股份有限公司新提交2件商标注册申请。商标申请详情如下:今年以来西藏多瑞医药股份有限公司新申请注册商标2件,截止目前公司共持有注册商标106件,另有10件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000022855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2442480179","title":"多瑞医药(301075)6月7日主力资金净买入24.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442480179","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442480179?lang=zh_cn&edition=full","pubTime":"2024-06-11 09:13","pubTimestamp":1718068400,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月7日收盘,多瑞医药报收于16.3元,上涨6.19%,换手率6.41%,成交量1.76万手,成交额2842.71万元。近5日资金流向一览见下表:多瑞医药融资融券信息显示,融资方面,当日融资买入95.96万元,融资偿还231.62万元,融资净偿还135.66万元。多瑞医药主营业务:化学药品制剂及其原料药的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100002082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2441069595","title":"多瑞医药(301075)股东西藏嘉康时代科技发展有限公司质押173万股,占总股本2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441069595","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441069595?lang=zh_cn&edition=full","pubTime":"2024-06-07 21:37","pubTimestamp":1717767432,"startTime":"0","endTime":"0","summary":"证券之星消息,多瑞医药6月7日公开信息显示,股东西藏嘉康时代科技发展有限公司向西藏优富小额贷款有限责任公司合计质押173.0万股,占总股本2.16%。质押详情见下表:截止本公告日,股东西藏嘉康时代科技发展有限公司已累计质押股份1517.44万股,占其持股总数的32.51%。多瑞医药主营业务:化学药品制剂及其原料药的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700047910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2437768252","title":"多瑞医药(301075.SZ)2023年度权益分派:每10股派1.25元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437768252","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437768252?lang=zh_cn&edition=full","pubTime":"2024-05-23 22:04","pubTimestamp":1716473071,"startTime":"0","endTime":"0","summary":"智通财经APP讯,多瑞医药(301075.SZ)发布公告,公司2023年年度权益分派方案为:以公司现有总股本剔除已回购股份后为基数,向全体股东每10股派1.25元人民币现金(含税),本次权益分派股权登记日为:2024年5月30日,除权除息日为:2024年5月31日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1125458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2434833485","title":"多瑞医药:公司暂无相关领域的布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2434833485","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434833485?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:05","pubTimestamp":1715331953,"startTime":"0","endTime":"0","summary":"证券之星消息,多瑞医药(301075)05月10日在投资者关系平台上答复投资者关心的问题。投资者:请问贵公司有合成生物相关领域的研究吗多瑞医药董秘:您好!感谢您的关注!公司暂无相关领域的布局,谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000031973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301075","BK0239"],"gpt_icon":0},{"id":"2430631282","title":"多瑞医药(301075)2024年一季报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2430631282","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430631282?lang=zh_cn&edition=full","pubTime":"2024-04-26 06:31","pubTimestamp":1714084281,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期多瑞医药发布2024年一季报。根据财报显示,本报告期中多瑞医药增收不增利。其中,毛利率39.48%,同比减39.02%,净利率-4.56%,同比减41.15%,销售费用、管理费用、财务费用总计3350.5万元,三费占营收比42.7%,同比减28.88%,每股净资产9.37元,同比减0.99%,每股经营性现金流-0.16元,同比减173.09%,每股收益-0.03元。公司最新一期年度报表的现金流为正,经营性现金流和利润稍微不匹配,问题不大。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042600014041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2429862435","title":"多瑞医药(301075.SZ)发布一季度业绩,净亏损253.73万元,同比扩大4.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429862435","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429862435?lang=zh_cn&edition=full","pubTime":"2024-04-24 18:24","pubTimestamp":1713954263,"startTime":"0","endTime":"0","summary":"智通财经APP讯,多瑞医药(301075.SZ)发布2024年第一季度报告,营业收入7845.74万元,同比增长0.48%;归属于上市公司股东的净亏损253.73万元,同比扩大4.97%;归属于上市公司股东的扣除非经常性损益的净亏损374.93万元,同比扩大1.4%;基本每股亏损0.03元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301075"],"gpt_icon":0},{"id":"2404333679","title":"多瑞医药:拟投资取得红熙医疗51%股权 进一步丰富公司业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2404333679","media":"财华社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2404333679?lang=zh_cn&edition=full","pubTime":"2024-01-17 18:38","pubTimestamp":1705487924,"startTime":"0","endTime":"0","summary":"多瑞医药(301075)公告称,为进一步丰富公司业务布局,创造新的利润增长点,公司近日签订《投资合作协议》,公司以0万元受让李占兵、田彬、张恒瑞、熊荣亮持有的红熙医疗科技(天津)有限公司51%的股权(未实缴),对应注册资本510万元。公司将向红熙医疗出资510万元,履行实缴出资的义务。","market":"hk","thumbnail":"https://www.finet.hk/images/news_default.jpg","type":0,"news_type":0,"thumbnails":["https://www.finet.hk/images/news_default.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/65a7aefd53243c07837546cb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["301075","BK0239","159891"],"gpt_icon":0},{"id":"2404830313","title":"多瑞医药(301075.SZ)拟控股红熙医疗 进入慢性肾病管理领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2404830313","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2404830313?lang=zh_cn&edition=full","pubTime":"2024-01-17 15:53","pubTimestamp":1705477980,"startTime":"0","endTime":"0","summary":"多瑞医药公告,公司近日签订了《投资合作协议》,公司以0万元受让李占兵、田彬、张恒瑞、熊荣亮持有的红熙医疗科技(天津)有限公司51%的股权(未实缴),对应注册资本510万元。公司将向红熙医疗出资510万元,履行实缴出资的义务。本次股权转让完成后,公司持有红熙医疗51%股权,红熙医疗为公司控股子公司。本次对外投资有利于公司进入慢性肾病管理领域,为公司创造新的利润增长点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-17/doc-inacvpix6383922.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-01-17/doc-inacvpix6383922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159891","301075","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2021-09-29","address":"西藏自治区昌都市卡若区经济技术开发区A区创业大道9号","stockEarnings":[{"period":"1week","weight":0.0053},{"period":"1month","weight":-0.0634},{"period":"3month","weight":-0.1289},{"period":"6month","weight":-0.3668},{"period":"1year","weight":-0.3678},{"period":"ytd","weight":-0.4307}],"companyName":"西藏多瑞医药股份有限公司","boardCode":"AI0027","perCapita":"2848股","boardName":"医药制造业","registeredCapital":"8000万元","compareEarnings":[{"period":"1week","weight":0.008},{"period":"1month","weight":-0.0176},{"period":"3month","weight":-0.0362},{"period":"6month","weight":0.0461},{"period":"1year","weight":-0.0735},{"period":"ytd","weight":-0.0041}],"survey":" 西藏多瑞医药股份有限公司主要从事化学药品制剂及其原料药的研发、生产和销售业务。公司的主要产品为醋酸钠林格注射液等。","serverTime":1721309270868,"listedPrice":27.27,"stockholders":"9628人(较上一季度减少9.30%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"多瑞医药,301075,多瑞医药股票,多瑞医药股票老虎,多瑞医药股票老虎国际,多瑞医药行情,多瑞医药股票行情,多瑞医药股价,多瑞医药股市,多瑞医药股票价格,多瑞医药股票交易,多瑞医药股票购买,多瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"多瑞医药(301075)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供多瑞医药(301075)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}